Vanguard Capital Management
LTRN icon

Vanguard Capital Management’s Lantern Pharma LTRN Stock Holding History

Vanguard Capital Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Buy
425,118
+93,039
+28% +$273K ﹤0.01% 3456
2026
Q1 		$455K Buy
+332,079
New +$929K ﹤0.01% 3691

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Vanguard Capital Management's LTRN Position: Q2 2026 in Review

Vanguard Capital Management increased its Lantern Pharma (LTRN) stake by 28% in Q2 2026, buying an estimated $273K and bringing the position to 425,118 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3456.

Vanguard Capital Management first reported a position in LTRN in Q1 2026 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Vanguard Capital Management held 425,118 shares of Lantern Pharma worth $1.77M as of Q2 2026.
  • Vanguard Capital Management bought 93,039 Lantern Pharma shares in Q2 2026, an estimated $273K.
  • Lantern Pharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3456 holding.
  • Vanguard Capital Management first reported a position in Lantern Pharma in Q1 2026 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.